Seroatlas · Human Serome Atlas

FCRL2

Fc receptor-like protein 2

Also known as: CD307b, FCRH2, FCRL2_HUMAN, IRTA4, SPAP1

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q96LA5
Gene: FCRL2
Ensembl: ENSG00000132704
Chromosome: 1
Canonical length: 508 aa
Protein class: CD markers, Predicted membrane proteins

OverviewNCBI Gene

This gene encodes a member of the immunoglobulin receptor superfamily and is one of several Fc receptor-like glycoproteins clustered on the long arm of chromosome 1. The encoded protein has four extracellular C2-type immunoglobulin domains, a transmembrane domain and a cytoplasmic domain that contains one immunoreceptor-tyrosine activation motif and two immunoreceptor-tyrosine inhibitory motifs. This protein may be a prognostic marker for chronic lymphocytic leukemia. Alternatively spliced transcript variants have been described, but their biological validity has not been determined. [provided by RefSeq, Apr 2009]

Canonical amino-acid sequenceUniProt

508 residues, UniProt reviewed canonical sequence.

>Q96LA5|FCRL2
     1  MLLWSLLVIF DAVTEQADSL TLVAPSSVFE GDSIVLKCQG EQNWKIQKMA YHKDNKELSV
    61  FKKFSDFLIQ SAVLSDSGNY FCSTKGQLFL WDKTSNIVKI KVQELFQRPV LTASSFQPIE
   121  GGPVSLKCET RLSPQRLDVQ LQFCFFRENQ VLGSGWSSSP ELQISAVWSE DTGSYWCKAE
   181  TVTHRIRKQS LQSQIHVQRI PISNVSLEIR APGGQVTEGQ KLILLCSVAG GTGNVTFSWY
   241  REATGTSMGK KTQRSLSAEL EIPAVKESDA GKYYCRADNG HVPIQSKVVN IPVRIPVSRP
   301  VLTLRSPGAQ AAVGDLLELH CEALRGSPPI LYQFYHEDVT LGNSSAPSGG GASFNLSLTA
   361  EHSGNYSCEA NNGLGAQCSE AVPVSISGPD GYRRDLMTAG VLWGLFGVLG FTGVALLLYA
   421  LFHKISGESS ATNEPRGASR PNPQEFTYSS PTPDMEELQP VYVNVGSVDV DVVYSQVWSM
   481  QQPESSANIR TLLENKDSQV IYSSVKKS

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against FCRL2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 1
Mean surface accessibility (rSASA): 0.4
Highest tissue expression: 33 nTPM

Expression across tissuesHPA

Tissue

spleen: 33 nTPM
tonsil: 24 nTPM
lymph node: 23 nTPM
small intestine: 20 nTPM
appendix: 12 nTPM
bone marrow: 2.5 nTPM

Single-cell type

b-cells: 141 nCPM
plasma cells: 55 nCPM
neutrophils: 6.9 nCPM
thymocytes: 5.9 nCPM
conjunctival goblet cells: 4.9 nCPM
gastric chief cells: 4.4 nCPM

Immune cell

memory B-cell: 30 nTPM
naive B-cell: 19 nTPM
basophil: 0.7 nTPM
total PBMC: 0.6 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM

Brain region

white matter: 3.6 nTPM
cerebral cortex: 3 nTPM
medulla oblongata: 3 nTPM
pons: 2.6 nTPM
hypothalamus: 2.5 nTPM
spinal cord: 2.5 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.12
gnomAD pLI: 0
gnomAD missense Z: -0.48
DepMap mean gene effect: 0
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 2% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of FCRL2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

PTPN6

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads FCRL2 as an antibody target. Whether an autoantibody or antibody against FCRL2 could matter depends on whether native FCRL2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

FCRL2 is annotated at the cell surface, where native FCRL2 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label FCRL2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...